Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 May 5:76:e2629.
doi: 10.6061/clinics/2021/e2629. eCollection 2021.

Guselkumab: widened action in psoriatic disease

Marcelo Arnone  1 , André Vicente Esteves de Carvalho  2 , Lincoln Zambaldi Fabricio  3 , Ricardo Romiti  1
Affiliations
Editorial

Guselkumab: widened action in psoriatic disease

Marcelo Arnone et al. Clinics (Sao Paulo). .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Main endpoints of interest (DISCOVER-2) (3).
See this image and copyright information in PMC

References

    1. Griffiths CEM, Papp K, Song M, Randazzo B, Li S, Shen YK, et al. Poster presented at: Falls Clinical Dermatology Conference. SKIN The Journal of Cutaneous Medicine. 2018. Maintenance of Response With Guselkumab for up to 3 Years’ Treatment in the Phase 3 VOYAGE 1 Trial of Patients With Plaque Psoriasis.
    1. Deodhar A, Helliwell PS, Boehncke WH, Kollmeier AP, Hsia EC, Subramanian RA, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115–25. doi: 10.1016/S0140-6736(20)30265-8. - DOI - PubMed
    1. Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126–36. doi: 10.1016/S0140-6736(20)30263-4. - DOI - PubMed
    1. Tremfya [package insert] Horsham (PA): Janssen Biotech, Inc. 2019.
    1. Puig L. Guselkumab for the treatment of adults with moderate to severe plaque psoriasis. Expert Rev Clin Immunol. 2019;15(6):589–97. doi: 10.1080/1744666X.2019.1601014. - DOI - PubMed

Publication types

Substances